Health Trials

Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic

ConditionNeurocognitive Disorders
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBaptist Health South Florida

About this trial

This is prospective observational registry study that will assess 1) if the neurocognitive function app (Brainlab Cognition) can be used in a widespread neuro-oncology clinic setting and 2) if patient reported quality of life parameters can be obtained electronically and integrated into clinic.

Eligibility criteria

Qualifiers

All adult (18+) patients with central nervous system (CNS) tumors, both primary brain malignancies and brain metastases, treated with radiotherapy (partial brain, stereotactic radiosurgery, stereotactic fractionated radiotherapy, or whole-brain radiotherapy), surgery, and/or antineoplastic therapy and followed thereafter at Miami Cancer Institute (MCI)

Life expectancy ≥ 6 months

Willingness to participate in ongoing registration study

Disqualifiers

Patients receiving radiotherapy to the brain for functional disease (arteriovenous malformations, trigeminal neuralgia, essential tremors, etc.)

Pediatric patients (<18 years old), pregnant women, and prisoners.

Trial design

Treatments tested in this trial

  • Observational study

Treatment groups

No treatment groups listed

Locations

1
Miami Cancer Institute33176, MiamiFlorida, United States

Sponsors and collaborators

Baptist Health South Florida

Lead sponsor

Brainlab AG

Collaborator

Source ClinicalTrials.gov